Sign in →

Respiratory Panel by PCR

eD-H Order Code

LAB4063

Specimen Collection Information

Specimen Mininum Test Volume Container Special Handling
NP Swab 1.0 ML  

Specimen Transport Temperature

Refrigerated

Reference Ranges / Critical Values

Assay Gender Age Range Normal Range Critical Values Units
Adenovirus All 0 Minutes – 150 Years Not Detected
Bordetella pertussis All 0 Minutes – 150 Years Not Detected
Chlamydophila pneumoniae All 0 Minutes – 150 Years Not Detected
Coronavirus 229E All 0 Minutes – 150 Years Not Detected
Coronavirus HKU1 All 0 Minutes – 150 Years Not Detected
Coronavirus NL63 All 0 Minutes – 150 Years Not Detected
Coronavirus OC43 All 0 Minutes – 150 Years Not Detected
Human Metapneumovirus All 0 Minutes – 150 Years Not Detected
Human Rhinovirus/Enterovirus All 0 Minutes – 150 Years Not Detected
Influenza A All 0 Minutes – 150 Years Not Detected
Influenza A H1 All 0 Minutes – 150 Years Not Detected
Influenza A H1-2009 All 0 Minutes – 150 Years Not Detected
Influenza A H3 All 0 Minutes – 150 Years Not Detected
Influenza B All 0 Minutes – 150 Years Not Detected
Mycoplasma pneumoniae All 0 Minutes – 150 Years Not Detected
Parainfluenza 1 All 0 Minutes – 150 Years Not Detected
Parainfluenza 2 All 0 Minutes – 150 Years Not Detected
Parainfluenza 3 All 0 Minutes – 150 Years Not Detected
Parainfluenza 4 All 0 Minutes – 150 Years Not Detected
Respiratory Panel PCR All 0 Minutes – 150 Years Negative
Respiratory Syncytial Virus All 0 Minutes – 150 Years Not Detected
SARS-CoV-2 All 0 Minutes – 150 Years Not Detected

Specimen Stability

4 hours Ambient

72hrs Refrigerated

Assay Information

Assay Result Type
Respiratory Panel Source Alpha
Respiratory Panel PCR Alpha
Adenovirus Alpha
Coronavirus HKU1 Alpha
Coronavirus NL63 Alpha
Coronavirus 229E Alpha
Coronavirus OC43 Alpha
SARS-CoV-2 Alpha
Human Metapneumovirus Alpha
Human Rhinovirus/Enterovirus Alpha
Influenza A Alpha
Influenza A H1 Alpha
Influenza A H1-2009 Alpha
Influenza A H3 Alpha
Influenza B Alpha
Parainfluenza 1 Alpha
Parainfluenza 2 Alpha
Parainfluenza 3 Alpha
Parainfluenza 4 Alpha
Respiratory Syncytial Virus Alpha

Additional Specimen Instructions

Collect Nasopharyngeal flocked swab into universal transport media. See NP swab collection information here
Testing for an expanded panel of respiratory viruses (i.e. other than Influenza A/B and RSV) may be indicated in some immunocompromised and/or critically ill patients.


The respiratory panel includes the following: Adenovirus, Coronavirus HKU1, Coronavirus NL63, Coronavirus 229E, Coronavirus OC43, Human Metapneumovirus, Human Rhinovirus/Enterovirus, Influenza A, Influenza A H1, Influenza A H1-2009, Influenza A H3, Influenza B, Parainfluenza 1, Parainfluenza 2, Parainfluenza 3, Parainfluenza 4, Respiratory Syncytial Virus, Chlamydophila pneumoniae, Mycoplasma pneumoniae and SARS CoV-2.


Outpatients should be tested with the Rapid Influenza A/B and RSV PCR test (LAB 4035)

Interpretive Data

Assay Display Interpretive Data
Respiratory Panel PCR Respiratory Panels are performed on the FilmArray using multiplexed PCR nucleic acid detection. Negative results do not preclude respiratory infection and should not be used as the sole basis for diagnosis treatment or other management decisions.
SARS-CoV-2 Testing for SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) to aid in the diagnosis of COVID-19 is performed using the BioFire Respiratory Panel 2.1 (BioMerieux) as authorized by the FDA issued Emergency Use Authorization (EUA). This panel also tests for multiple other viral and bacterial pathogens. This assay is intended for In-vitro Diagnostic (IVD) use with nasopharyngeal swabs in viral transport media. The assay is performed based on the instructions for use and additional guidance provided by the FDA. Testing is performed in laboratories within the Dartmouth-Hitchcock Health System each of which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) 42 U.S.C. section 263a to perform high-complexity tests. Assay performance has been verified according to clinical laboratory regulatory requirements. The test result for SARS-CoV-2 provided above should be interpreted in combination with the clinical observation patient history and epidemiological information. For testing of asymptomatic individuals assay performance characteristics and clinical utility have not been evaluated. A result of “Not Detected” indicates that the viral RNA target is not present but does not preclude SARS-CoV-2 infection. False negative results may occur if a specimen is improperly collected transported or handled; if amplification inhibitors are present; or if inadequate numbers of viral particles are present in the specimen. When a diagnostic test is negative the possibility of a false negative result should be considered in the context of a patient’s recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. A result of “Detected” suggests a current or recent infection. Positive and negative predictive values for this test are dependent on disease prevalence. A result of “Invalid” indicates the inability to conclusively determine the presence or absence of SARS-CoV-2 RNA in the sample which can be due to a variety of factors. Collection of a new sample for repeat testing is recommended in the case of an invalid result. CDC COVID-19 criteria for testing on human specimens and clinical management guidance information are available at the CDC Coronavirus Disease 2019 (COVID-19) webpage under “Information for Healthcare Professionals” (https://www.cdc.gov/coronavirus/2019-ncov/hcp/index.html). Additional information about this and other EUA tests can be found in provider and patient fact sheets at the following FDA website: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas

Day(s) Performed

Monday through Sunday; continuously

CPT(s)

87633 ; 87486 ; 87581

Performing Lab Section

Microbiology